-
Mubritinib (TAK 165): A Mitochondrial Lens
2026-10-04
Mubritinib and TAK 165 are best interpreted through mitochondrial dependency rather than HER2 activity alone. This article connects cancer biology with a cardiac OXPHOS study to clarify evidence strength, translational boundaries, and research questions.
-
MLN8237 (Alisertib): Aurora A Evidence Guide
2026-10-03
MLN8237, also called Alisertib, is a supplier-described selective Aurora A kinase inhibitor for cancer biology research. Product data report nanomolar biochemical potency, while a peer-reviewed aneugenicity study provides a framework for interpreting mitotic-kinase effects without establishing MLN8237-specific activity.
-
Mubritinib (TAK 165): Complex I Workflow
2026-10-02
Mubritinib (TAK 165) is most useful as a mitochondrial complex I and oxidative phosphorylation probe, not simply as a legacy HER2 kinase tool. This workflow connects viability, ROS, mitochondrial potential, apoptosis, and cisplatin-sensitization assays across AML, PEL, and NSCLC models while highlighting practical controls for reproducibility.
-
GPR68 Inhibition, Ferroptosis, and Radiosensitivity
2026-10-01
A 2025 Scientific Reports study identifies GPR68 inhibition as a trigger of ferroptosis and a sensitizer to ionizing radiation in lung and pancreatic cancer cell models. Its experiments connect acidic-tumor-microenvironment signaling with intracellular ferrous iron mobilization, lipid peroxidation, and reduced colony growth in both 2D and 3D cultures.
-
GSH-Responsive MOF Nanoparticles for Melanoma Therapy
2026-10-01
Hao et al. developed ICG-MOF-SS-AUNP12, a glutathione-responsive metal–organic framework nanoparticle that combines near-infrared photothermal therapy with PD-1/PD-L1 checkpoint blockade. The study shows how stimulus-responsive release and immune activation can be integrated into one platform while also highlighting the need for quantitative efficacy, safety, and translational studies.
-
Gap26: Decoding Cx43 Inflammation Signaling
2026-09-30
Gap26 is a connexin 43 mimetic peptide for dissecting how Cx43 links intercellular communication with NF-κB-driven inflammation. This guide translates macrophage evidence into practical assay decisions, controls, and cross-domain applications.
-
Cathepsin B inhibitor CA-074: Lab Workflow
2026-09-30
This practical guide explains how to use CA-074 to test cathepsin B-dependent proteolysis in biochemical, cellular, cancer metastasis, neurotoxicity, and immune-response workflows. It is suitable for controlled research assays, but product-dossier findings should not be treated as universal cell potency, clinical evidence, or a substitute for orthogonal target-validation methods.
-
SIRT3-SUMO, N-Glycosylation, and Asthma Tregs
2026-09-29
This study links SIRT3 SUMOylation to Treg differentiation and asthma through fatty acid oxidation, acetyl-CoA availability, and N-glycosylation substrate production. Its combined computational, cellular, molecular, and in vivo design provides a mechanistic framework for understanding how metabolic regulation may influence both Th2 and non-Th2 asthma phenotypes.
-
SmD2 Acetylation Links Splicing to PARP Sensitivity
2026-09-29
This 2024 Nature Communications study identifies acetylation-dependent control of the spliceosomal protein SmD2 as a mechanistic link between alternative splicing, DNA-damage repair, and PARP-inhibitor response in hepatocellular carcinoma. The work supports a preclinical strategy combining HDAC-directed intervention with olaparib, particularly in models where conventional PARP-inhibitor sensitivity is limited.
-
Annexin V-Cy5: Reading Apoptosis in Microglia
2026-09-28
Annexin V apoptosis detection can help determine whether microglial dysfunction includes phosphatidylserine exposure—or instead reflects impaired lysosomal processing without cell death. This article develops an interpretation-led workflow grounded in a reversible zebrafish lysosomal-stress study.
-
Isochlorogenic acid A: Hydrogel Research Workflow
2026-09-27
Explore how Isochlorogenic acid A can move from solvent-controlled natural product assays into Fe(III)-coassembled hydrogel studies. A recent wound-repair study offers useful formulation and assay benchmarks, while this workflow separates reported findings from practical starting conditions that require local optimization.
-
How GCG Disrupts SARS-CoV-2 Nucleocapsid Condensation
2026-09-26
The study links RNA-triggered liquid–liquid phase separation of SARS-CoV-2 nucleocapsid protein to viral infection and reports that (-)-gallocatechin gallate (GCG) disrupts this condensation while inhibiting viral replication. Its findings establish N-protein condensation as a mechanistic research direction, while leaving important questions about specificity, in vivo relevance, and therapeutic potential open.
-
Carbapenemase Spread in Guangdong CREC
2026-09-26
A multicenter study of 54 carbapenem-resistant Enterobacter cloacae isolates found frequent carbapenemase-encoding genes, predominantly blaNDM-1, and high in-vitro transfer of these genes. By combining resistance testing, gene-location analysis, conjugation assays, and strain typing, the work distinguishes the potential contributions of mobile genetic elements and related bacterial strains to dissemination.
-
Dacarbazine In Vitro: Workflow & Troubleshooting
2026-09-25
Use Dacarbazine to probe DNA-damage responses while separating growth inhibition from actual cell killing. This workflow pairs fresh-solution handling and time-resolved viability measurements with an orthogonal death readout for more interpretable cancer-model comparisons.
-
HNF4A-AS1 Links Lipid Reprogramming to Sorafenib Resistance
2026-09-25
A 2024 study connects reduced HNF4A-AS1 to sorafenib resistance in hepatocellular carcinoma through METTL3- and YTHDF3-linked regulation of DECR1 mRNA, lower PUFA abundance, and reduced ferroptosis sensitivity. Its combination of molecular assays, lipidomics, organoids, and xenografts supports a mechanistic model, while leaving clinical validation and the relevance of other metabolic readouts as open questions.